#BEGIN_DRUGCARD DB00727

# AHFS_Codes:
24:12.08
92:02.00*

# ATC_Codes:
C01DA02

# Absorption:
Not Available

# Biotransformation:
Hepatic, cytochrome P450 (P450) is a key enzyme of organic nitrate biotransformation

# Brand_Mixtures:
Alchemed NP-03 (aconite + apis mellifica + arnica montana + barberry root + calendula + cantharides + charcoal activated + echinacea angustifolia + hahnemann's causticum + hypericum perforatum + nitroglycerin + urtica urens)
Alchemed NP-04 (aesculus hippocastanum + arnica montana + barium carbonate + belladonna + celandine + cinchona officinalis + nitroglycerin + oyster shells + sepia officinalis l + strophanthus hispidus)
Alchemed NP-21 (belladonna + cantharides + german chamomile + nitroglycerin + phosphorus + sepia officinalis l + silver nitrate + valerian + zinc)
Aribosan B31 - liq (apis mellifica + barberry root + colchicine + convallaria majalis + nitroglycerin + poison oak + potassium iodide + quinine dihyrochloride)
CRC-plex (arnica montana + barium chloride + calcium lactate + charcoal activated + cholesterol + convallaria majalis + epinephrine + iodine + magnesium carbonate + nitroglycerin + phosphorus + picric acid + potassium iodide + strophanthus hispidus)
Cactus Compositum DPS (cactus grandiflorus + nitroglycerin + potassium carbonate + spigelia)
Cere Bosan B36 - liq (belladonna + hamamelis virginiana + nitroglycerin + saffron + trillium pendulum)
Complex 12 (aesculus hippocastanum + apis mellifica + arnica montana + barium carbonate + barium chloride + belladonna + calcium fluoride + celandine + charcoal activated + cinchona officinalis + collinsonia canadensis + conium maculatum + echinacea angustifolia + hamamelis virginiana + lycopodium clavatum + nitroglycerin + phosphorus + ruta graveolens + sepia officinalis l + sodium chloride + strophanthus hispidus + sulfur + tobacco)
Complex 15 (belladonna + cimicifuga racemosa + cinchona officinalis + glycyrrhiza glabra + nitroglycerin + oyster shells + platinum + pulsatilla + sanguinaria canadensis + sepia officinalis l + sulfur + tiger lily + vitex agnus castus)
Ero-bosan B20-liq (nitroglycerin + pulsatilla + sanguinaria canadensis + sepia officinalis l + vitex agnus castus)
From time to time (belladonna + bryonia + charcoal activated + gelsemium sempervirens + lycopodium clavatum + melilot + nitroglycerin + silicon dioxide + sodium chloride + spigelia marylandica)
Globuli no 51 (barium carbonate + cactus grandiflorus + gelsemium sempervirens + nitroglycerin)
HPB Complex DPS (barium chloride + gold + mistletoe + nitroglycerin)
Homeo-form MI - liquid (aluminum oxide + antimony trisulfide + cyclamen europaeum l. + lycopodium clavatum + melilot + nitroglycerin + silver nitrate)
Homeo-form MI-tab (aluminum oxide + antimony trisulfide + cyclamen europaeum l. + lycopodium clavatum + melilot + nitroglycerin + silver nitrate)
Homeodel 24 (belladonna + charcoal activated + gelsemium sempervirens + iris versicolor + lycopodium + nitroglycerin + spigelia)
Homeopathic Remedy THC no.4 (aconite + arnica montana + belladonna + bryonia + cocculus indicus + gelsemium sempervirens + iris versicolor + lycopodium clavatum + nitroglycerin + potassium dichromate + pulsatilla + sanguinaria canadensis + silicon dioxide + silver nitrate + sodium chloride + spigelia marylandica + thuja occidentalis)
Ingr-bosan b34 - liq (belladonna + cimicifuga racemosa + gelsemium sempervirens + iris versicolor + nitroglycerin + spigelia anthelmia)
Iper-bosan b44 - liq (baryta iodata + cactus grandiflorus + gelsemium sempervirens + nitroglycerin)
L.122 - liq orl (bryonia + cactus grandiflorus + nitroglycerin + potassium carbonate)
L.15 DPS (aconitinum + apocynum cannabinum + arnica montana + cactus grandiflorus + nitroglycerin)
L.73 liq (belladonna + cocculus indicus + lead acetate + mugwort + nitroglycerin + periwinkle + pulsatilla + silver nitrate + valerian)
L2 (apis mellifica + belladonna + juglans cinerea + nitroglycerin + phytolacca decandra + pulsatilla + spongia tosta + vitex agnus castus)
Nova - 7041 - liq (belladonna + cantharides + german chamomile + nitroglycerin + phosphorus + sepia officinalis l + silver nitrate + valerian + zinc)
Nova 7025 - liq (aconite + apis mellifica + arnica montana + barberry root + calendula + cantharides + charcoal activated + echinacea angustifolia + hahnemann's causticum + hypericum perforatum + nitroglycerin + urtica urens)
Nova 7028 - liq (aesculus hippocastanum + arnica montana + barium carbonate + belladonna + calcium carbonate + celandine + cinchona officinalis + nitroglycerin + sepia officinalis l + strophanthus hispidus)
Nova 7037 - liq (belladonna + calcium carbonate + cinchona officinalis + nitroglycerin + platinum + pulsatilla + sanguinaria canadensis + sulfur + tiger lily + tin)
Pekana - complex nr. 47 (clematis erecta + cynara scolymus + dulcamara + euphrasia officinalis + ivy + nitroglycerin + ruta graveolens + tobacco)
R 47 dps (asafetida + coffee + musk + nitroglycerin + pulsatilla)
R-12 dps (arnica montana + barium chloride + calcium iodide + conium maculatum + lead acetate + nitroglycerin + phosphorus + potassium iodide)
R12 (arnica montana + barium chloride + calcium iodide + conium maculatum + lead acetate + nitroglycerin + phosphorus + potassium iodide)
R47 (asafetida + coffee + musk + nitroglycerin + pulsatilla)
THC complex #15 (belladonna + cinchona officinalis + gelsemium sempervirens + nitroglycerin + sodium chloride + sulfur)
THC complex #2 (aconite + apis mellifica + arnica montana + belladonna + bryonia + cocculus indicus + ferrum phosphoricum + gelsemium sempervirens + hydrastis canadensis + iris versicolor + lycopodium clavatum + magnesium phosphate dibasic + nitroglycerin + phosphorus + potassium dichromate + potassium phosphate dibasic + pulsatilla + sanguinaria canadensis + silicon dioxide + silver nitrate + sodium chloride + spigelia marylandica + thuja occidentalis)
THC complex #37 (aconite + bellis perennis + caulophyllum thalictroides + cimicifuga racemosa + nitroglycerin + pulsatilla + sanguinaria canadensis + strontium carbonate)

# Brand_Names:
Cellegesic
Minitran
Natispray
Nitro-Dur
Nitrocap
Nitrolingual Pump Spray
Nitronet
Nitrong parenteral
Nitrospan
Nitrostat
Rectogesic
Transderm Nitro
Tridil

# CAS_Registry_Number:
55-63-0

# ChEBI_ID:
28787

# Chemical_Formula:
C3H5N3O9

# Chemical_IUPAC_Name:
2,3-bis(nitrooxy)propyl nitrate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
1926454

# Description:
A volatile vasodilator which relieves angina pectoris by stimulating guanylate cyclase and lowering cytosolic calcium. [PubChem]

# Dosage_Forms:
Aerosol, metered	Sublingual
Disc	Transdermal
Liquid	Intravenous
Liquid	Oral
Ointment	Topical
Patch	Transdermal
Solution	Intravenous
Solution / drops	Oral
Spray, metered	Sublingual
Tablet	Oral
Tablet	Sublingual

# Drug_Category:
Explosive Agents
Nitrates and Nitrites
Tocolytic Agents
Vasodilator Agents

# Drug_Interactions:
Alteplase	IV nitroglycerin may decrease the effect of alteplase.
Avanafil	Additive vasodilation. Concomitant therapy is contraindicated.
Azilsartan medoxomil	Pharmacodynamic synergist- increases effects.
Dihydroergotamine	Possible antagonism of action
Dihydroergotoxine	Possible antagonism of action
Ergonovine	Possible antagonism of action
Ergotamine	Possible antagonism of action
Methylergonovine	Possible antagonism of action
Methysergide	Possible antagonism of action
Sildenafil	Possible significant hypotension with this combination
Tadalafil	The vasodilatory effects of Nitroglycerin may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
Treprostinil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Udenafil	The vasodilatory effects of Nitroglycerin may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.
Vardenafil	The vasodilatory effects of Nitroglycerin may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.62

# Experimental_Logs:
-2.22

# Experimental_Water_Solubility:
1380 mg/L (at 20 °C)

# Food_Interactions:
Avoid alcohol.
Dissolve under the tongue.
Take on empty stomach: 1 hour before or 2 hours after meals.

# GenBank_ID:
Not Available

# Generic_Name:
Nitroglycerin

# HET_ID:
Not Available

# Half_Life:
3 minutes

# InChI_Identifier:
InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2

# InChI_Key:
InChIKey=SNIOPGDIGTZGOP-UHFFFAOYSA-N

# Indication:
For the prevention of angina

# KEGG_Compound_ID:
C07455

# KEGG_Drug_ID:
D00515

# LIMS_Drug_ID:
727

# Mechanism_Of_Action:
Similar to other nitrites and organic nitrates, nitroglycerin is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase. This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.

# Melting_Point:
13.5 °C

# Molecular_Weight_Avg:
227.0865

# Molecular_Weight_Mono:
227.002578773

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nit1296.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450644

# Pharmacology:
Nitroglycerin, an organic nitrate, is available in many forms as a vasodilator. Nitroglycerin is used in the treatement of angina pectoris and perioperative hypertension, to produce controlled hypotension during surgical procedures, to treat hypertensive emergencies, and to treat congestive heart failure associated with myocardial infarction.

# Predicted_LogP_Hydrophobicity:
1.25

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
2.04e-01 g/l

# Primary_Accession_No:
DB00727

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4510

# PubChem_Substance_ID:
46509120

# RxList_Link:
http://www.rxlist.com/cgi/generic/ntg.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00153

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Glyceryl trinitrate
NG
NTG
Nitroglycerine
TNG
Trinitroglycerin
nitroglycerin ointment

# Synthesis_Reference:
Not Available

# Toxicity:
Increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; Vertigo; Palpitations; Visual disturbances; Nausea and vomiting (possibly with colic and even bloody diarrhea); Syncope (especially in the upright posture); Air hunger and dyspnea, later followed by reduced ventilatory effort; Diaphoresis, with the skin either flushed or cold and clammy; Heart block and bradycardia; Paralysis; Coma; Seizures; Death.

# Update_Date:
2013-02-08 16:19:35 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nitroglycerin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
ALDH2

# Phase_1_Metabolizing_Enzyme_1_ID:
147

# Phase_1_Metabolizing_Enzyme_1_Name:
Aldehyde dehydrogenase, mitochondrial

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Aldehyde dehydrogenase, mitochondrial precursor
MLRAAARFGPRLGRRLLSAAATQAVPAPNQQPEVFCNQIFINNEWHDAVSRKTFPTVNPS
TGEVICQVAEGDKEDVDKAVKAARAAFQLGSPWRRMDASHRGRLLNRLADLIERDRTYLA
ALETLDNGKPYVISYLVDLDMVLKCLRYYAGWADKYHGKTIPIDGDFFSYTRHEPVGVCG
QIIPWNFPLLMQAWKLGPALATGNVVVMKVAEQTPLTALYVANLIKEAGFPPGVVNIVPG
FGPTAGAAIASHEDVDKVAFTGSTEIGRVIQVAAGSSNLKRVTLELGGKSPNIIMSDADM
DWAVEQAHFALFFNQGQCCCAGSRTFVQEDIYDEFVERSVARAKSRVVGNPFDSKTEQGP
QVDETQFKKILGYINTGKQEGAKLLCGGGIAADRGYFIQPTVFGDVQDGMTIAKEEIFGP
VMQILKFKTIEEVVGRANNSTYGLAAAVFTKDLDKANYLSQALQAGTVWVNCYDVFGAQS
PFGGYKMSGSGRELGEYGLQAYTEVKTVTVKVPQKNS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05091

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
12890708	Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003 Aug;139(7):1289-96.
19732062	Bauersachs J: Aminoethyl nitrate--the novel super nitrate? Br J Pharmacol. 2009 Sep;158(2):507-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
NPR1

# Drug_Target_1_GenBank_ID_Gene:
X15357

# Drug_Target_1_GenBank_ID_Protein:
28230

# Drug_Target_1_GeneCard_ID:
NPR1

# Drug_Target_1_Gene_Name:
NPR1

# Drug_Target_1_Gene_Sequence:
>3186 bp
ATGCCGGGGCCCCGGCGCCCCGCTGGCTCCCGCCTGCGCCTGCTCCTGCTCCTGCTGCTG
CCGCCGCTGCTGCTGCTGCTCCGGGGCAGCCACGCGGGCAACCTGACGGTAGCCGTGGTA
CTGCCGCTGGCCAATACCTCGTACCCCTGGTCGTGGGCGCGCGTGGGACCCGCCGTGGAG
CTGGCCCTGGCCCAGGTGAAGGCGCGCCCCGACTTGCTGCCGGGCTGGACGGTCCGCACG
GTGCTGGGCAGCAGCGAAAACGCGCTGGGCGTCTGCTCCGACACCGCAGCGCCCCTGGCC
GCGGTGGACCTCAAGTGGGAGCACAACCCCGCTGTGTTCCTGGGCCCCGGCTGCGTGTAC
GCCGCCGCCCCAGTGGGGCGCTTCACCGCGCACTGGCGGGTCCCGCTGCTGACCGCCGGC
GCCCCGGCGCTGGGCTTCGGTGTCAAGGACGAGTATGCGCTGACCACCCGCGCGGGGCCC
AGCTACGCCAAGCTGGGGGACTTCGTGGCGGCGCTGCACCGACGGCTGGGCTGGGAGCGC
CAAGCGCTCATGCTCTACGCCTACCGGCCGGGTGACGAAGAGCACTGCTTCTTCCTCGTG
GAGGGGCTGTTCATGCGGGTCCGCGACCGCCTCAATATTACGGTGGACCACCTGGAGTTC
GCCGAGGACGACCTCAGCCACTACACCAGGCTGCTGCGGACCATGCCGCGCAAAGGCCGA
GTTATCTACATCTGCAGCTCCCCTGATGCCTTCAGAACCCTCATGCTCCTGGCCCTGGAA
GCTGGCTTGTGTGGGGAGGACTACGTTTTCTTCCACCTGGATATCTTTGGGCAAAGCCTG
CAAGGTGGACAGGGCCCTGCTCCCCGCAGGCCCTGGGAGAGAGGGGATGGGCAGGATGTC
AGTGCCCGCCAGGCCTTTCAGGCTGCCAAAATCATTACATATAAAGACCCAGATAATCCC
GAGTACTTGGAATTCCTGAAGCAGTTAAAACACCTGGCCTATGAGCAGTTCAACTTCACC
ATGGAGGATGGCCTGGTGAACACCATCCCAGCATCCTTCCACGACGGGCTCCTGCTCTAT
ATCCAGGCAGTGACGGAGACTCTGGCACATGGGGGAACTGTTACTGATGGGGAGAACATC
ACTCAGCGGATGTGGAACCGAAGCTTTCAAGGTGTGACAGGATACCTGAAAATTGATAGC
AGTGGCGATCGGGAAACAGACTTCTCCCTCTGGGATATGGATCCCGAGAATGGTGCCTTC
AGGGTTGTACTGAACTACAATGGGACTTCCCAAGAGCTGGTGGCTGTGTCGGGGCGCAAA
CTGAACTGGCCCCTGGGGTACCCTCCTCCTGACATCCCCAAATGTGGCTTTGACAACGAA
GACCCAGCATGCAACCAAGATCACCTTTCCACCCTGGAGGTGCTGGCTTTGGTGGGCAGC
CTCTCCTTGCTCGGCATTCTGATTGTCTCCTTCTTCATATACAGGAAGATGCAGCTGGAG
AAGGAACTGGCCTCGGAGCTGTGGCGGGTGCGCTGGGAGGACGTTGAGCCCAGTAGCCTT
GAGAGGCACCTGCGGAGTGCAGGCAGCCGGCTGACCCTGAGCGGGAGAGGCTCCAATTAC
GGCTCCCTGCTAACCACAGAGGGCCAGTTCCAAGTCTTTGCCAAGACAGCATATTATAAG
GGCAACCTCGTGGCTGTGAAACGTGTGAACCGTAAACGCATTGAGCTGACACGAAAAGTC
CTGTTTGAACTGAAGCATATGCGGGATGTGCAGAATGAACACCTGACCAGGTTTGTGGGA
GCCTGCACCGACCCCCCCAATATCTGCATCCTCACAGAGTACTGTCCCCGTGGGAGCCTG
CAGGACATTCTGGAGAATGAGAGCATCACCCTGGACTGGATGTTCCGGTACTCACTCACC
AATGACATCGTCAAGGGCATGCTGTTTCTACACAATGGGGCTATCTGTTCCCATGGGAAC
CTCAAGTCATCCAACTGCGTGGTAGATGGGCGCTTTGTGCTCAAGATCACCGACTATGGG
CTGGAGAGCTTCAGGGACCTGGACCCAGAGCAAGGACACACCGTTTATGCCAAAAAGCTG
TGGACGGCCCCTGAGCTCCTGCGAATGGCTTCACCCCCTGTGCGGGGCTCCCAGGCTGGT
GACGTATACAGCTTTGGGATCATCCTTCAGGAGATTGCCCTGAGGAGTGGGGTCTTCCAC
GTGGAAGGTTTGGACCTGAGCCCCAAAGAGATCATCGAGCGGGTGACTCGGGGTGAGCAG
CCCCCCTTCCGGCCCTCCCTGGCCCTGCAGAGTCACCTGGAGGAGTTGGGGCTGCTCATG
CAGCGGTGCTGGGCTGAGGACCCACAGGAGAGGCCACCATTCCAGCAGATCCGCCTGACG
TTGCGCAAATTTAACAGGGAGAACAGCAGCAACATCCTGGACAACCTGCTGTCCCGCATG
GAGCAGTACGCGAACAATCTGGAGGAACTGGTGGAGGAGCGGACCCAGGCATACCTGGAG
GAGAAGCGCAAGGCTGAGGCCCTGCTCTACCAGATCCTGCCTCACTCAGTGGCTGAGCAG
CTGAAGCGTGGGGAGACGGTGCAGGCCGAAGCCTTTGACAGTGTTACCATCTACTTCAGT
GACATTGTGGGTTTCACAGCGCTGTCGGCGGAGAGCACACCCATGCAGGTGGTGACCCTG
CTCAATGACCTGTACACTTGCTTTGATGCTGTCATAGACAACTTTGATGTGTACAAGGTG
GAGACAATTGGCGATGCCTACATGGTGGTGTCAGGGCTCCCTGTGCGGAACGGGCGGCTA
CACGCCTGCGAGGTAGCCCGCATGGCCCTGGCACTGCTGGATGCTGTGCGCTCCTTCCGA
ATCCGCCACCGGCCCCAGGAGCAGCTGCGCTTGCGCATTGGCATCCACACAGGACCTGTG
TGTGCTGGAGTGGTGGGACTGAAGATGCCCCGTTACTGTCTCTTTGGGGATACAGTCAAC
ACAGCCTCAAGAATGGAGTCTAATGGGGAAGCCCTGAAGATCCACTTGTCTTCTGAGACC
AAGGCTGTCCTGGAGGAGTTTGGTGGTTTCGAGCTGGAGCTTCGAGGGGATGTAGAAATG
AAGGGCAAAGGCAAGGTTCGGACCTACTGGCTCCTTGGGGAGAGGGGGAGTAGCACCCGA
GGCTGA

# Drug_Target_1_General_Function:
Signal transduction mechanisms

# Drug_Target_1_General_References:
2569967	Lowe DG, Chang MS, Hellmiss R, Chen E, Singh S, Garbers DL, Goeddel DV: Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. EMBO J. 1989 May;8(5):1377-84.
7954658	Pardhasaradhi K, Kutty RK, Gentleman S, Krishna G: Expression of mRNA for atrial natriuretic peptide receptor guanylate cyclase (ANPRA) in human retina. Cell Mol Neurobiol. 1994 Feb;14(1):1-7.
9618281	Takahashi Y, Nakayama T, Soma M, Izumi Y, Kanmatsuse K: Organization of the human natriuretic peptide receptor A gene. Biochem Biophys Res Commun. 1998 May 29;246(3):736-9.

# Drug_Target_1_HGNC_ID:
HGNC:7943

# Drug_Target_1_HPRD_ID:
00165

# Drug_Target_1_ID:
613

# Drug_Target_1_Locus:
1q21-q22

# Drug_Target_1_Molecular_Weight:
118921

# Drug_Target_1_Name:
Atrial natriuretic peptide receptor A

# Drug_Target_1_Number_of_Residues:
1061

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00211	Guanylate_cyc
PF01094	ANF_receptor
PF07714	Pkinase_Tyr

# Drug_Target_1_Protein_Sequence:
>Atrial natriuretic peptide receptor A precursor
MPGPRRPAGSRLRLLLLLLLPPLLLLLRGSHAGNLTVAVVLPLANTSYPWSWARVGPAVE
LALAQVKARPDLLPGWTVRTVLGSSENALGVCSDTAAPLAAVDLKWEHNPAVFLGPGCVY
AAAPVGRFTAHWRVPLLTAGAPALGFGVKDEYALTTRAGPSYAKLGDFVAALHRRLGWER
QALMLYAYRPGDEEHCFFLVEGLFMRVRDRLNITVDHLEFAEDDLSHYTRLLRTMPRKGR
VIYICSSPDAFRTLMLLALEAGLCGEDYVFFHLDIFGQSLQGGQGPAPRRPWERGDGQDV
SARQAFQAAKIITYKDPDNPEYLEFLKQLKHLAYEQFNFTMEDGLVNTIPASFHDGLLLY
IQAVTETLAHGGTVTDGENITQRMWNRSFQGVTGYLKIDSSGDRETDFSLWDMDPENGAF
RVVLNYNGTSQELVAVSGRKLNWPLGYPPPDIPKCGFDNEDPACNQDHLSTLEVLALVGS
LSLLGILIVSFFIYRKMQLEKELASELWRVRWEDVEPSSLERHLRSAGSRLTLSGRGSNY
GSLLTTEGQFQVFAKTAYYKGNLVAVKRVNRKRIELTRKVLFELKHMRDVQNEHLTRFVG
ACTDPPNICILTEYCPRGSLQDILENESITLDWMFRYSLTNDIVKGMLFLHNGAICSHGN
LKSSNCVVDGRFVLKITDYGLESFRDLDPEQGHTVYAKKLWTAPELLRMASPPVRGSQAG
DVYSFGIILQEIALRSGVFHVEGLDLSPKEIIERVTRGEQPPFRPSLALQSHLEELGLLM
QRCWAEDPQERPPFQQIRLTLRKFNRENSSNILDNLLSRMEQYANNLEELVEERTQAYLE
EKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTL
LNDLYTCFDAVIDNFDVYKVETIGDAYMVVSGLPVRNGRLHACEVARMALALLDAVRSFR
IRHRPQEQLRLRIGIHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGEALKIHLSSET
KAVLEEFGGFELELRGDVEMKGKGKVRTYWLLGERGSSTRG

# Drug_Target_1_Reaction:
GTP = 3',5'-cyclic GMP + diphosphate

# Drug_Target_1_Signals:
1-32

# Drug_Target_1_Specific_Function:
Receptor for atrial natriuretic peptide. Has guanylate cyclase activity on binding of ANF

# Drug_Target_1_SwissProt_ID:
P16066

# Drug_Target_1_SwissProt_Name:
ANPRA_HUMAN

# Drug_Target_1_Synonyms:
ANP-A
ANPRA
Atrial natriuretic peptide A-type receptor
Atrial natriuretic peptide receptor A precursor
EC 4.6.1.2
GC-A
Guanylate cyclase
NPR-A

# Drug_Target_1_Theoretical_pI:
6.61

# Drug_Target_1_Transmembrane_Regions:
474-494

#END_DRUGCARD DB00727
